With 2.68 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.18 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $43.8741 whereas the lowest price it dropped to was $42.71. The 52-week range on EXEL shows that it touched its highest point at $49.62 and its lowest point at $21.82 during that stretch. It currently has a 1-year price target of $44.16. Beta for the stock currently stands at 0.28.
Price Performance and Earnings:
Three-month performance surged to 16.43% while six-month performance rose 29.44%. The stock gained 29.40% in the past year, while it has gained 93.06% so far this year. A look at the trailing 12-month EPS for EXEL yields 2.20 with Next year EPS estimates of 3.18. For the next quarter, that number is 0.64. This implies an EPS growth rate of 51.04% for this year and 19.53% for next year. EPS is expected to grow by 32.33% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 11.55%.
Float and Shares Shorts:
At present, 275.03 million EXEL shares are outstanding with a float of 263.89 million shares on hand for trading. On 2025-06-13, short shares totaled 20.39 million, which was 748.0 higher than short shares on 1747267200. In addition to Dr. Stelios Papadopoulos Ph.D. as the firm’s Co-Founder & Independent Chair of the Board, Dr. Michael M. Morrissey Ph.D. serves as its CEO, President & Director.
Institutional Ownership:
Through their ownership of 0.94067 of EXEL’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, EXEL reported revenue of $555447000.0 and operating income of $186859000.0. The EBITDA in the recently reported quarter was $194204000.0 and diluted EPS was $0.55.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EXEL since 8 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With EXEL analysts setting a high price target of 60.0 and a low target of 29.0, the average target price over the next 12 months is 44.15789. Based on these targets, EXEL could surge 39.24% to reach the target high and fall by -32.7% to reach the target low. Reaching the average price target will result in a growth of 2.48% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.67424 being high and $0.48775 being low. For EXEL, this leads to a yearly average estimate of $0.61686. Based on analyst estimates, the high estimate for the next quarter is $0.86 and the low estimate is $0.49. The average estimate for the next quarter is thus $0.68.
